Page 45 - GB-RI-PierreFabre-Complet-INTERACTIF

4 41 CREATING VALUE 5 Driven by its Purpose, the Pierre Fabre Group strives to redistribute the value it creates among all its stakeholders. • Up to 756 safety and efficacy tests conducted before and after sending a dermo-cosmetic product to market* • €127m invested in global R&D to discover new treatments, primarily in oncology and dermatology, and new dermo-cosmetics products • 30 international patient associations collaborating with us on new products, services or digital apps • 1,668 people registered on the POP Training platform (674 pharmacists, 339 pharmacy students, and 255 pharmacy technicians) to improve the care for eczema patients • Dermaweb, an international dermatology information and discussion platform for over 22,000 dermatologists of which 18% are European • Nearly 200,000 units of PPE, hand sanitizer, soap, Thermal Spring Water sprays and creams distributed to over 70 French hospitals, care homes and medical centers during the pandemic • No. 1 private employer in the French department of the Tarn • 10% of employees benefit from internal mobility • 92,391 hours of training for skills development • +102.5% rise in the par value of company shares since the launch of the employee shareholder scheme in 2005 • 7.23% of workforce employed from the disabled sector in France vs. national average of 4% • 3 million face masks issued to employees during the pandemic • €10m allocated to the Pierre Fabre Foundation in 2020 for grants and dividends • €78m invested in the South-West • 97% of plants used by our brands are harvested with no loss of sustainability • 5,000 hygiene and beauty kits issued to students at 9 campuses in Occitania as part of the “Bien manger pour tous” (Good Food For All) campaign run by the regional council during the pandemic. The Pierre Fabre Foundation: main recipient of dividends The Pierre Fabre Foundation is the Group’s biggest shareholder owning a 86% capital stake. Recognized as a public interest organization, its primary mission is to improve access to essential care and medicines for people in emerging countries. Each year it receives 86% of the dividends paid by the company, as well as grants, so that it can perform its mission independently, as per its constitution. *Example of a sterile product intended for infants with atopic skin